HDAC6 and cancer: To the best of our knowledge, this is the first study to demonstrate the use of polymeric nanoformulation of PI3‐Kδ/HDAC6 dual inhibitor (HSB‐510) to improve the efficacy and safety of dual inhibitor molecules for cancer therapy.